Over 90 clinical trials in phase I-IV are underway assessing NRF-2 (nuclear factor (erythroid-derived 2) – like 2) activators in cardiovascular disease and its comorbid conditions [116, 117]. The gene discussed is NFE2L2; the disease is cardiovascular disorder.